#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
wasinington,	D.C.	20343

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     SUN ANTHONY Y		2. Issuer Name <b>and</b> Ticker or Trading Symbol <b>Zentalis Pharmaceuticals</b> , <b>Inc.</b> [ ZNTL ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
		Zentalis Pharmaceuticals, Inc. [ ZN1L ]						X Direct		10% Owr			ner					
(Last)	(Fi	rst) (N	Middle)	3 Date of Farli	$\dashv$	X Office below	er (give /)	e title Other (sp below)			ecify							
, ,	•	IARMACEUTIC	•	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2022							President & CEO							
1359 BR	OADWAY	SUITE 1710																
(0)		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)									
(Street) NEW YORK NY 10018										X Form filed by One Reporting Person								
											Form filed by More than One Reporting Person							
(City)	(Si	ate) (2	Zip)															
		Table	I - Non-Deriva	tive Securiti	es Acq	uired	l, Dispos	ed of,	or Ben	efici	ally Own	ed						
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Yea	3. Transa Code (		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		d 5)	5. Amount Securities Beneficially Owned Following		6. Owner Form: Di (D) or Indirect ( (Instr. 4)	rect (I)	Indirec Benefic	7. Nature of ndirect Beneficial Ownership Instr. 4)				
				Code	v	Amount (A) or (D) Price		Price		Reported Transaction(s) (Instr. 3 and 4)								
Common	Stock		02/01/2022		S <sup>(1)</sup>		4,124	D	\$56.80	)96 <sup>(2)</sup>	1,188,593		B D					
Common	Stock		02/01/2022		S <sup>(1)</sup>		3,419	D	\$57.62	273 <sup>(3)</sup>	<sup>3)</sup> 1,185,174		I D					
Common	Stock		02/01/2022		S <sup>(1)</sup>		2,828	D	\$58.58	372 <sup>(4)</sup>	1,182,346		D					
Common	Stock		02/01/2022		S <sup>(1)</sup>		100	D	\$59.	.31	1,182,246		D					
Common	Stock		02/02/2022		S <sup>(1)</sup>		8,128	D	\$57.87	724 <sup>(5)</sup>	5) 1,174,118		D					
Common	Stock		02/02/2022		S <sup>(1)</sup>		2,343	D	\$58.29	923 <sup>(6)</sup>	(6) 1,171,775		D					
Common	Stock										103,650		I		By Spouse			
Common	Stock										974,30	)2	I		By Es Group Intern LLC			
Common	Stock										213,600		I	1 *				
Common Stock										125,000		I						
		Tal	ole II - Derivati (e.g., pu	ve Securities			•				•	t						
1. Title of Derivative Security (Instr. 3)	L. Title of 2. 3. Transaction Date Execution Date, (Month/Day/Year)		4. 5. Number 6. Dat Expire		e Exercisable and Amount of Securities Underlying Derivative Security (1 3 and 4)		nd of s ng	8. Price of Derivative Security (Instr. 5)			Ownership of Form: Edirect (D) C		11. Nature of Indirect Beneficial Ownership (Instr. 4)					
	n of Pasnon			Code V (A	) (D)	Date Exerc		iration e	or Nu of	ımber								

- 1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
- 2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$56.21 to \$57.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$57.21 to \$58.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$58.24 to \$59.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$57.16 to \$58.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 6. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$58.16 to \$58.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 7. Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC

except to the extent of his pecuniary interest therein, if any.

8. Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.

## Remarks:

By: /s/ Melissa B. Epperly, Attorney-in-Fact for Anthony 02/03/2022 Y. Sun

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.